CYC065: Clinical Trials

3 trials of CYC065, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting, 1 suspended, 1 unknown. 3 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Recruiting 1, Suspended 1, Unknown 1
Phase 23Recruiting 1, Suspended 1, Unknown 1

Follow CYC065: new trials by email Literature Review of CYC065 trials Research Report on CYC065

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
fadraciclib - Leukemia, Myelodysplastic Syndrome(MDS)
Phase 1 / Phase 2SuspendedCyclacel Pharmaceuticals, Inc.2102021-10-222024-02-08
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Fadraciclib - Solid Tumor, Adult, Lymphoma
Phase 1 / Phase 2UnknownCyclacel Pharmaceuticals, Inc.3302021-07-122024-01-25
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Ribociclib, Topotecan, Temozolomide - Pediatric Cancer
Phase 1 / Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris4722016-08-032026-07-10

Conditions studied

Leukemia (1)  ·  Lymphoma (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasms (1)

Sponsors

Cyclacel Pharmaceuticals, Inc. (2)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)

Countries

Spain (2)  ·  United States (2)  ·  Denmark (1)  ·  France (1)  ·  Italy (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Birgit Geoerger, MD (1)  ·  Mark H Kirschbaum, MD (1)

Results publications

PMID 31538815, PMID 33892407, PMID 34347542, PMID 34543871, PMID 35292802, PMID 41838385, PMID 42686334

NIH funding

2016 (1)